🔎Breaking new ground in liver fibrosis detection! Our paper introduces the CLivD score, enhancing FIB-4 performance in the US general population. Explore how this innovation elevates liver health assessment. 🔗egastroenterology.bmj.com/content/1/2/e1… #LiverFibrosis #CLivD #FIB4 #MedicalResearch

Great vibes at the ALD posters today! Thanks to all presenters for fantastic introductions to their work 🙏 #EASLcongress

In a >23k general population sample 👥, risks for liver outcomes were 4x higher in MetALD and 8x higher in ALD vs MASLD. 96% of ALD pts 🧑‍⚕️ had metabolic risk factors ⚠️. 🍷Alcohol use < MASLD limits detrimental. 🙏 talented Ville Männistö bit.ly/3WmlY2w

Alcohol contributes to liver risk in all subtypes of #SLD Hepatology Communications doi.org/10.1016/j.jhep…

ALD worse than MetALD worse than MASLD? Yes, says the FINRISK cohort Ville Männistö JHEP Reports ✅ follow up >13 yrs ✅nationwide registry outcome data ❌SLD diagnosed by ALT≥20 IU/L ❌Few events despite 23,900 participants 🔗doi.org/10.1016/j.jhep…

How to assess/quantify alcohol use in clinical trials and clinical practice? Self reported good enough? CDT or Peth better? Check out 👇👇 sciencedirect.com/science/articl…

Less=More w #antibiotics in #cirrhosis & ✅ reconsider #SecSBPProphylaxis AJG - The American Journal of Gastroenterology⤵️ pubmed.ncbi.nlm.nih.gov/39235290/ 🔑#SecSBPPr vs others▶️⬆️SBP recurrence &🚫mortality benefit 🔑2 datasets (VA Research & @TriNetX) w similar trends 🔑worsens over time & validated locally Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟

🚨 Comparing tacrolimus vs cyclosporine after liver transplantation for PBC: 📌 No signif. survival difference overall 📌 TAC beneficial in specific cases: post-2000, women, 6-mth landmark analysis 📌 CyA did not reduce graft loss or recurrence markers 👉 bit.ly/4h1ez21

📢New release: Updated EASL Clinical Practice Guidelines on Liver Transplantation (LT) . These guidelines, last updated in 2016, have undergone a major overhaul to incorporate the latest advancements in the field. 🔍 New assessment techniques: Better tools to evaluate liver

🔍 Exploring alcohol and cardiometabolic risk factors in #SLD: Where do we stand? Join #EASLStudio for a thought-provoking discussion with experts Aleksander Krag, Maja Thiele, Fredrik Åberg, and Maru Rinella MD. 🗓️ Wednesday, 20 November | 18:00 CET 🔗 easl.eu/easl-studio-ep…

Thanks to HEPATOLOGY Journal for this ALD issue & the chance to review this alarming global crisis 🚨🌎: >11M life-years lost annually, leading cause of liver Tx, and rising impact on young people 🙏 Amazing team⭐️ Ville Männistö Z. Gordon Jiang Helena Cortez Pinto journals.lww.com/hep/fulltext/2…

🎬 What’s on #EASLStudio this week? Hear insights from Aleksander Krag in this short preview! 🗓️ Wednesday, 20 November | 18:00 CET 🔗 easl.eu/easl-studio-ep… @EASLNews Maja Thiele Fredrik Åberg Maru Rinella MD

Now Online! Hepatology Special issue on alcohol-associated liver disease. #LiverX journals.lww.com/hep/pages/curr…

Now on demand 👉Alcohol, cardiometabolic risk factors and #SLD 📺Watch here: easlcampus.eu/videos/easl-st… 🎧 Listen Here: easlcampus.eu/podcasts/easl-… If you are interested in steatotic liver disease, the next *EASL SLD Summit 2025* is for you! 🗓️ 23-25 January 2025 in Estoril, Portugal

Don’t miss this December ENTIRE issue of HEPATOLOGY Journal dedicated to #ALD Presented here by Dr. Michael R. Lucey UW School of Medicine and Public Health AASLD Watch: buff.ly/41JYkRG

Just out 🚨: The impact of 56 genetic variants associated with steatotic liver disease in 595 donor-recipient liver transplant pairs with >7yr-median follow-up and protocol liver biopsies 🧬 👇 pubmed.ncbi.nlm.nih.gov/40087975/

To Screen—or not to screen for for advanced steatotic liver disease? Our new The Lancet Gastroenterology & Hepatology review re-examines Wilson & Jungner (1968), weighs today’s evidence, and proposes 2025 screening criteria Stine Johansen authors.elsevier.com/c/1lRV98nByrGW…